Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

$5.18

-0.12 (-2.26%)

07:52
12/10/18
12/10
07:52
12/10/18
07:52

Marinus Pharmaceuticals announces results from two ganaxolone studies

Marinus Pharmaceuticals announced "positive" results from its Phase 2 clinical trials evaluating ganaxolone intravenous, or IV, and oral in women with postpartum depression, or PPD. Based on these results, the company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens. There was a clear dose response relationship seen for three groups of patients receiving ganaxolone IV at median doses of 60, 90 and 140 microg/kg/h.The 140 microg/kg/h dose group demonstrated the most robust results, with a clinically meaningful 5.6-point reduction in Hamilton Rating Scale for Depression, or HAM-D17, compared to placebo at 48 hours that was durable through the last visit, day 34. These patients had a mean HAM-D17 reduction of 16.9 and 15.7 points from baseline at 60 hours and day 34, respectively. Overall, 75% of patients were responders, as defined as having a 50% reduction from baseline, at day 34 and 67% were responders at 60 hours. Additionally, 50% of patients achieved remission from depression, as determined by a HAM-D17 of 7, at day 34 and 33% achieved remission at 60 hours. Ganaxolone was safe and well-tolerated in all dose groups. Consistent with previous ganaxolone studies, the most common reported adverse events were sedation and dizziness. There were no serious adverse events reported, no discontinuations due to a treatment related adverse event and consistent with prior studies, there were no reports of syncope or loss of consciousness. The Clinical Global Impression of Improvement, or CGI-I, as well as the Edinburgh Postnatal Depression Survey, or EPDS, and Spielberger State-Trait Anxiety 6, or STAI-6, showed highly similar trends that were consistent with HAM-D17. Overall, 58 patients with PPD were randomized on a 1:1 basis to receive one of three ascending fixed IV 60-hour dose regimens of ganaxolone or placebo. No initial up titration was required and patients were down titrated over the final 12 hours of the 60-hour infusion. A bolus injection of ganaxolone prior to the 60-hour infusion was explored to test the safety and tolerability of a very short, high dose infusion. None of the dose groups were powered to generate statistical significance. Patients with a HAM-D17 score of 26 were considered for enrollment in the study. HAM-D17 measurements were conducted by a centralized rater and taken at various timepoints spanning from baseline to day 34. Enrollment is ongoing in the company's oral study, a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of oral ganaxolone in women with PPD. Patients with a HAM-D17 score of 20 but less than 26 are being considered for enrollment in the study. Cohorts of patients enrolled in the initial open label phase of the study receive ascending dose regimens with oral ganaxolone. The efficacy endpoint is change from baseline in the HAM-D17 score. Patients in the most recent dose cohort who took oral ganaxolone for four weeks had a mean HAM-D17 reduction of 13.2 points 28 days from a baseline of 24.7 and a reduction of 15.7 points at day 36. This cohort is on-going and not all patients have reached day 28. As with IV, oral ganaxolone was generally safe and well-tolerated with no serious adverse events reported and no discontinuations due to treatment related adverse events. The company is advancing both the Magnolia and Amaryllis studies with data expected in the first half of 2019. The second part of the Magnolia Study will evaluate a short IV infusion followed by oral ganaxolone administration and the Amaryllis study will continue to optimize oral ganaxolone dosing.

MRNS Marinus Pharmaceuticals
$5.18

-0.12 (-2.26%)

07/19/18
MZHO
07/19/18
NO CHANGE
Target $13
MZHO
Buy
Marinus can rally 100% on postpartum depression data, says Mizuho
Mizuho analyst Difei Yang believes Marinus Pharmaceuticals' Q3 top-line data from part 1 of the Phase 2 Magnolia study of ganaxolone IV in women with postpartum depression will be an "important catalyst" for the shares. The analyst sees upside potential of 100%-plus, assuming "convincing data including a clear dose response." She believes the downside is limited given the history of the compound and potential in other indications. Yang reiterates a Buy rating on Marinus with a $13 price target.
07/02/18
CANT
07/02/18
INITIATION
Target $19
CANT
Overweight
Marinus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Marinus Pharmaceuticals with an Overweight rating and $19 price target. The analyst views the stock's risk/reward as compelling into upcoming data catalysts for ganaxolone, a positive allosteric modulator of GABAA receptor.
06/06/18
LTCO
06/06/18
INITIATION
Target $20
LTCO
Buy
Marinus Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Marinus Pharmaceuticals with a Buy rating and $20 price target.
05/24/18
05/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) initiated with an Outperform at Evercore ISI. 2. Caesars (CZR) initiated with an Overweight at JPMorgan. 3. e.l.f. Beauty (ELF) initiated with an Outperform at Oppenheimer. 4. uniQure (QURE) initiated with a Buy at SunTrust. 5. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WBA

Walgreens Boots Alliance

$62.35

0.09 (0.14%)

10:46
11/12/19
11/12
10:46
11/12/19
10:46
Recommendations
Walgreens Boots Alliance analyst commentary  »

Walgreens Boots could be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 22

    Nov

QSR

Restaurant Brands

$67.39

-0.15 (-0.22%)

10:45
11/12/19
11/12
10:45
11/12/19
10:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
11/12/19
11/12
10:45
11/12/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

10:45
11/12/19
11/12
10:45
11/12/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

F

Ford

$9.11

0.03 (0.33%)

, GM

General Motors

$38.89

0.18 (0.46%)

10:38
11/12/19
11/12
10:38
11/12/19
10:38
Periodicals
Trump expected to extend deadline for EU car tariffs, Bloomberg says »

The Trump administration…

F

Ford

$9.11

0.03 (0.33%)

GM

General Motors

$38.89

0.18 (0.46%)

HMC

Honda

$29.35

0.15 (0.51%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$145.00

-0.07 (-0.05%)

TSLA

Tesla

$348.78

3.71 (1.08%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.21

0.1 (0.62%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

KSS

Kohl's

$56.48

-0.56 (-0.98%)

10:35
11/12/19
11/12
10:35
11/12/19
10:35
Options
Kohl's put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

10:35
11/12/19
11/12
10:35
11/12/19
10:35
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

DIS

Disney

$139.04

2.3 (1.68%)

10:31
11/12/19
11/12
10:31
11/12/19
10:31
Hot Stocks
Disney says Disney+ 'exceeded our high expectations,' working on glitches »

Disney+ Help tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$32.77

0.01 (0.03%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Options
Kraft Heinz call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
Roche to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

REPL

Replimune Group

$17.24

0.11 (0.64%)

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
Replimune Group participates in a conference call with JPMorgan »

SMid Biotech Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

10:25
11/12/19
11/12
10:25
11/12/19
10:25
Conference/Events
UBS technology analysts to hold an analyst/industry conference call »

Technology Analysts…

LH

LabCorp

$165.45

-0.29 (-0.17%)

10:23
11/12/19
11/12
10:23
11/12/19
10:23
Syndicate
Breaking Syndicate news story on LabCorp »

LabCorp files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$47.57

1.39 (3.01%)

, TEVA

Teva

$9.36

0.03 (0.32%)

10:21
11/12/19
11/12
10:21
11/12/19
10:21
On The Fly
JPMorgan gets less bearish on Xerox among today's top calls on Wall Street »

Check out today's top…

CRWD

Crowdstrike

$47.57

1.39 (3.01%)

TEVA

Teva

$9.36

0.03 (0.32%)

AMRX

Amneal Pharmaceuticals

$2.69

0.05 (1.89%)

XRX

Xerox

$38.05

-0.28 (-0.73%)

HPQ

HP Inc.

$19.33

-0.31 (-1.58%)

AMAT

Applied Materials

$56.81

0.21 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 26

    Nov

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

UCBJY

UCB

$0.00

(0.00%)

10:20
11/12/19
11/12
10:20
11/12/19
10:20
Conference/Events
UCB participates in a conference call with JPMorgan »

European Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.92

3.02 (17.87%)

10:18
11/12/19
11/12
10:18
11/12/19
10:18
On The Fly
Analysts see good odds of Amarin's Vascepa label expansion after docs posted »

Stifel analyst Derek…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/12/19
11/12
10:17
11/12/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

, CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ARLO

Arlo Technologies

$2.84

0.18 (6.77%)

CCC

Clarivate Analytics

$17.22

0.13 (0.76%)

STOK

Stoke Therapeutics

$30.87

1.04 (3.49%)

BMRN

BioMarin

$75.96

0.72 (0.96%)

BIIB

Biogen

$291.50

-2.41 (-0.82%)

AMGN

Amgen

$223.35

2.66 (1.21%)

CTVA

Corteva

$27.06

0.32 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

  • 09

    Dec

CSX

CSX

$72.89

-1.04 (-1.41%)

, ETN

Eaton

$91.78

-0.09 (-0.10%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Initiation
Fly Intel: Top five analyst downgrades »

Catch up on today's…

CSX

CSX

$72.89

-1.04 (-1.41%)

ETN

Eaton

$91.78

-0.09 (-0.10%)

AMRX

Amneal Pharmaceuticals

$2.71

0.07 (2.65%)

ALB

Albemarle

$67.47

-0.25 (-0.37%)

BOX

Box

$15.93

-0.52 (-3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 12

    Dec

ARGO

Argo Group

$63.82

2.54 (4.14%)

, LYV

Live Nation

$64.79

0.32 (0.50%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

ARGO

Argo Group

$63.82

2.54 (4.14%)

LYV

Live Nation

$64.79

0.32 (0.50%)

RCII

Rent-A-Center

$23.13

0.78 (3.49%)

CRWD

Crowdstrike

$47.25

1.07 (2.32%)

TEVA

Teva

$9.40

0.07 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$138.17

1.43 (1.05%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Periodicals
Disney tells CNBC streaming service launch exceeds 'high expectations' »

CNBC reported via Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.90

-0.01 (-0.17%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Options
Sprint put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IDRA

Idera Pharmaceuticals

$2.29

0.06 (2.69%)

10:15
11/12/19
11/12
10:15
11/12/19
10:15
Conference/Events
Idera Pharmaceuticals participates in a conference call with JPMorgan »

SMid Biotech Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$138.25

1.51 (1.10%)

10:12
11/12/19
11/12
10:12
11/12/19
10:12
Periodicals
Disney working to fix Disney+ issues amid 'incredible response,' TechCrunch says »

Disney+ users have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.